Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 347 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Statin Clear all
Completed Phase 2 Interventional

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

NCT01912560
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
CAT-2003, Placebo, Statin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Muscle Shoals, Alabama • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 18, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

NCT00729027
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
25 mg/day AVE5530, 50 mg/day AVE5530, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Not applicable Interventional

Best Practice Advisory to Initiate High-Intensity Statin Therapy in Patients With Peripheral Artery Disease

NCT05166187
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Best Practice Advisory
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 18, 2026, 7:06 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Muscle Characteristics Associated With Statin Therapy

NCT00990834
View directory record Official record
Conditions
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Myopathy
Interventions
simvastatin
Drug
Lead sponsor
Scripps Health
Other
Eligibility
21 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 18, 2026, 7:06 AM EDT
Terminated Phase 3 Interventional Results available

Ezetimibe in Patients Hypo-responsive to Statins

NCT00965055
View directory record Official record
Conditions
High Cholesterol, Coronary Artery Disease
Interventions
Ezetimibe, Atorvastatin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 4 Interventional

To Investigate the Role of Upstream High Dose Statin in STEMI

NCT01050348
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Atorvastatin calcium, Inactive Placebo
Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
25 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Not applicable Interventional

Promoting Cholesterol Screening

NCT01930149
View directory record Official record
Conditions
Cardiovascular Diseases, Lipid Testing, Primary Prevention of Cardiovascular Disease
Interventions
Mailed patient outreach intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Flagstaff, Arizona • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 2 Interventional

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

NCT01893515
View directory record Official record
Conditions
Dyslipidemia
Interventions
PRC-4016, Placebo
Drug
Lead sponsor
Pronova BioPharma
Industry
Eligibility
18 Years to 79 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
39
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

NCT01350141
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
Placebo, PF-04950615 (RN316)
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
29
States / cities
Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

NCT01644188
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Ezetimibe, Placebo (for ezetimibe), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both

NCT00461968
View directory record Official record
Conditions
Cholesterol, LDL
Interventions
Ezetimibe and Simvastatin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 70 Years · Male only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2007 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Rifampin and Fluvastatin

NCT04029584
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
rifampin IV, Rifadin 300Mg Capsule, Fluvastatin 20 MG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Statin Therapy in the Treatment of Sepsis

NCT00676897
View directory record Official record
Conditions
Septic Shock
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 18, 2026, 7:06 AM EDT
Recruiting Phase 4 Interventional

Statins to Prevent Cancer Associated Blood Clots

NCT07303816
View directory record Official record
Conditions
Venous Thromboembolism, Cancer, Cardiovascular Events
Interventions
Rosuvastatin, Placebo Drug
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
9
States / cities
Irvine, California • New Haven, Connecticut • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 7:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol

NCT01200836
View directory record Official record
Conditions
Healthy Volunteers, Statins, Immune Modulation
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

NCT01236365
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin Placebo
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 20 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
5
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 2 Interventional Results available

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

NCT01525407
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Atorvastatin Calcium, Peripheral Blood Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Stanford, California • Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

NCT02993406
View directory record Official record
Conditions
Cardiovascular Diseases, Statin Adverse Reaction
Interventions
Bempedoic acid 180 mg tablet, Matching placebo tablet
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
13,970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
304
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 246 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

NCT01979601
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LGT209, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami Gardens, Florida • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 3 Interventional

Rho Kinase in Patients With Atherosclerosis

NCT00115830
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin, Rosuvastatin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2007 · Synced Oct 18, 2026, 7:06 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Trilipix Effects on Lipids and Arteries

NCT01025492
View directory record Official record
Conditions
Dyslipidemia
Interventions
Trilipix, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Phase 4 Interventional

Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

NCT00303277
View directory record Official record
Conditions
Alzheimer's Disease, Aging
Interventions
simvastatin, pravastatin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Oct 18, 2026, 7:06 AM EDT
Completed Not applicable Interventional

Increasing Medication Adherence Through Physician Incentives and Messaging

NCT01603329
View directory record Official record
Conditions
Medication Adherence
Interventions
Increasing Medication Adherence through Physician Incentives and Messaging
Other
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
65 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 18, 2026, 7:06 AM EDT
Recruiting Phase 2 Interventional

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

NCT04915183
View directory record Official record
Conditions
Hearing Loss, Head and Neck Cancer
Interventions
Placebo, Atorvastatin
Other · Drug
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 18, 2026, 7:06 AM EDT